Clinical Efficacy of Two Different Dentifrice Formulations in Treatment of Chronic Periodontitis

DYPV/EC/883/22/B

The study will be a single center, longitudinal prospective, triple blind (investigators, patients and statistician), randomized design. After informed consent, a target population of about 75 healthy adult volunteers with periodontitis will be included in the study. Patients will be randomized and categorized into three experimental groups each containing 25 patients. The randomization process will be carried out by use of sequentially numbered opaque sealed envelopes (SNOSE method).The recording of all the soft tissues data plaque index, gingival index, the modified sulcus bleeding index and the periodontal probing depth and clinical attachment level will be carried out at baseline, 4 weeks, 8 weeks, 12 weeks and will be maintained till 24 weeks for efficacy and safety evaluation.

2023-08-01

2023-10-15

2023-11-15

Recruiting

Early phase I

75

Inclusion Criteria: * 1.The patient should be in good general health as determined by the Investigator/ medical expert; 2.The patient should agree not to participate in any other oral/dental product studies during the course of this study; 3.The patient should agree to delay any dental treatment until the study has been completed; 4.The patient should agree to abstain from the use of any non-study oral hygiene products; 5.The patient should exhibit adequate oral hygiene (i.e., brush teeth daily and exhibit no signs of oral neglect); 6.The patient should agree to return for all scheduled visits and follow study procedures; 7.The patient should have a minimum of 20 teeth 8.The periodontal status of the patient should be Mild to moderate periodontitis (AAP classification 1999) 9.The oral status of the patient should be as follows: Plaque index (Silness \& Löe 1964)\>2 Gingival Index (Löe and Silness 1963) \>1.5 Modified Sulcus Bleeding Index (Mombelli et al 1987) \>1 PPD \> 4mm Exclusion Criteria: * 1.Presence of any condition, abnormality or situation at baseline that in the opinion of the Principal Investigator may preclude the volunteer's ability to comply with study requirements, including completion of the study or the quality of the data 2.Pregnant females 3.Patients having history of Tobacco use 4.Patients with Sjögren's disease 5.Patients having immune deficiency diseases, i.e., HIV or AIDS 6.Patients with poorly controlled diabetes mellitus 7.Patients taking anti TNF-alpha medication for rheumatoid arthritis 8.Patients taking anti-inflammatory, analgesic, or psychotropic drugs, 9.Patients having self-reported eating disorders, uncontrolled gastroesophageal reflux disease (GERD or Acid Reflux), excessive dietary or environmental exposure to acids, or other systemic conditions that are predisposing to dentinal hypersensitivity; 10.Patients with a history or presence of kidney disorders, kidney stones, celiac disease, inflammatory bowel disease (ulcerative colitis or Crohn's disease), chronic pancreatitis, have had intestinal or weight-loss surgery, or if have stomach or intestinal problems that keep them from absorbing certain foods or nutrients; 11.The teeth will be excluded from study measurements if they have deep, defective, or facial restorations; have full crowns, extensive caries, cracked enamel, or are abutment teeth for fixed or removable prosthesis; 12.The teeth having endo-perio lesion.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 75, 'type': 'ESTIMATED'}}

2023-09-21